# Effect of Cytochrome P 450 3A4 Inhibition by Itraconazole on the Single Oral Dose Pharmacokinetics of Cilobradine

> **NCT02264041** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 25 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Cilobradine, low dose
- **DRUG:** Cilobradine, high dose
- **DRUG:** Itraconazole

## Key facts

- **NCT ID:** NCT02264041
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** 2004-04
- **Final completion:** —
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2014-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02264041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02264041, "Effect of Cytochrome P 450 3A4 Inhibition by Itraconazole on the Single Oral Dose Pharmacokinetics of Cilobradine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02264041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*